Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 3 10Phase 1 3Phase 2/3 2Phase 1/2 2Phase EARLY_PHASE1 1

Status

Recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Renal Pelvis and Ureter Urothelial Carcinoma 1Osteosarcoma 1

Interventions

Cisplatin 17Magnetic Resonance Spectroscopy 16Specimen Handling 13pembrolizumab 10Carboplatin 10Gemcitabine 9Paclitaxel 8Radiotherapy 7Radiation 7Platinum 71,2-diaminocyclohexaneplatinum II citrate 7Pemetrexed 6Nivolumab 6Doxorubicin 6Surgical Procedures, Operative 5Radiotherapy, Intensity-Modulated 5Docetaxel 5Dexamethasone 5Biopsy 5atezolizumab 4Rituximab 4Immunoglobulin G 4Disulfides 4Bevacizumab 4Temozolomide 3Standard of Care 3Ramucirumab 3Drug Therapy 3Cyclophosphamide 3Cetuximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Methotrexate × 30 days × Clear all
NCT05691478 2026-05-27

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

National Cancer Institute (NCI)

Phase 2/3 Recruiting
1,122 enrolled
Sarcoma

Osteosarcoma

NCT04628767 2026-05-13

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
249 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡